TB-500 (10mg)

TB-500 (10mg): Synthetic Thymosin Beta-4 (Tβ4) Active Fragment — the 43-Amino-Acid Peptide with the Sequence Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser, Identical to the Naturally Occurring Thymosin Beta-4 Protein, Used in Research for Tissue Repair, Wound Healing, Cardioprotection, Neuroprotection, and Anti-Inflammatory Effects

TB-500 is a synthetic 43-amino-acid peptide that is identical in sequence to the naturally occurring protein thymosin beta-4 (Tβ4) — a small, highly conserved actin-binding protein found in virtually all mammalian cells and tissues. Its sequence is Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser (N-terminally acetylated, with a molecular weight of approximately 4963 Da). Thymosin beta-4 was first isolated from calf thymus in 1966 by Goldstein and colleagues as part of the "thymosin" family of peptides, and it was subsequently found to be the most abundant member of the beta-thymosin family, present in high concentrations in many cell types — particularly platelets, neutrophils, and macrophages, where it can constitute up to 20-30% of total cellular protein. Despite its name ("thymosin"), Tβ4 is NOT exclusively a thymic hormone — it is a ubiquitous intracellular and extracellular protein with diverse biological functions. The name "TB-500" is a research/brand name used for synthetic thymosin beta-4 in the research peptide community (it is sometimes also called "Tβ4," "thymosin beta-4," or "thymosin β4"). TB-500 has been extensively studied in preclinical research for its remarkable tissue repair and regenerative properties, with demonstrated effects in wound healing, cardiac repair after myocardial infarction, neuroprotection, corneal wound healing, liver repair, lung injury repair, and anti-inflammatory effects. The primary mechanism of action of Tβ4 is its ability to bind and sequester monomeric actin (G-actin), preventing its polymerization into filamentous actin (F-actin) — this makes Tβ4 the major actin-sequestering protein in most mammalian cells, regulating actin cytoskeleton dynamics, cell migration, cell shape changes, and intracellular transport. Beyond actin binding, Tβ4 has numerous other biological activities that contribute to its regenerative properties: (1) Promotion of cell migration — Tβ4 enhances migration of endothelial cells (angiogenesis), keratinocytes (re-epithelialization), fibroblasts (collagen deposition), stem/progenitor cells (tissue regeneration), and immune cells (wound clearance); this is mediated through actin cytoskeleton regulation, chemokine signaling, and activation of cell migration pathways; (2) Angiogenesis (new blood vessel formation) — Tβ4 promotes endothelial cell migration, proliferation, and tube formation, increasing blood vessel density in healing tissues; this is critical for delivering oxygen and nutrients to repairing tissue and removing waste; (3) Anti-inflammatory effects — Tβ4 reduces inflammation by inhibiting pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6, IFN-γ), reducing neutrophil infiltration and reactive oxygen species (ROS) production, promoting macrophage polarization toward the anti-inflammatory/pro-healing M2 phenotype, and inhibiting NF-κB signaling (a master regulator of inflammation); (4) Anti-apoptotic (cell survival) effects — Tβ4 inhibits apoptosis (programmed cell death) in various cell types (cardiomyocytes, neurons, endothelial cells, keratinocytes) by modulating apoptotic pathways (Bcl-2/Bax ratio, caspase inhibition, Akt/PI3K survival pathway activation); (5) Antioxidant effects — Tβ4 reduces oxidative stress by scavenging ROS, enhancing endogenous antioxidant defenses (superoxide dismutase, catalase, glutathione), and reducing oxidative damage to lipids, proteins, and DNA; (6) Stem cell activation and differentiation — Tβ4 activates resident stem/progenitor cells in various tissues (cardiac progenitor cells, neural stem cells, epidermal stem cells, mesenchymal stem cells), promoting their proliferation, migration to injury sites, and differentiation into tissue-specific cell types; (7) Extracellular matrix (ECM) remodeling — Tβ4 modulates ECM production and degradation, promoting organized collagen deposition (rather than excessive scarring), regulating matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), and reducing fibrosis/scar formation; (8) Cardioprotection — Tβ4 has demonstrated potent cardioprotective effects in preclinical models of myocardial infarction (heart attack), ischemia-reperfusion injury, heart failure, and cardiotoxicity; mechanisms include: reduced infarct size, increased cardiomyocyte survival, enhanced angiogenesis in ischemic myocardium, reduced fibrosis/scarring, improved cardiac function, and activation of cardiac progenitor cells; (9) Neuroprotection — Tβ4 has neuroprotective effects in models of stroke, traumatic brain injury, spinal cord injury, neurodegenerative diseases (Alzheimer's, Parkinson's, multiple sclerosis), and peripheral nerve injury; mechanisms include: reduced neuronal apoptosis, reduced neuroinflammation, enhanced angiogenesis in brain, promoted neurite outgrowth and synaptic plasticity, improved functional recovery, and activation of neural stem cells; (10) Wound healing — Tβ4 accelerates wound healing in various models (skin wounds, burns, diabetic wounds, corneal wounds, oral wounds, surgical wounds) by promoting all phases of healing: inflammation (regulated), re-epithelialization (keratinocyte migration), granulation tissue formation (fibroblasts, angiogenesis), ECM remodeling, and wound closure; it is particularly effective in impaired healing (diabetic wounds, aged wounds, ischemic wounds); (11) Corneal repair — Tβ4 has been studied in clinical trials for corneal wound healing and dry eye syndrome; it promotes corneal epithelial cell migration and wound closure, reduces corneal inflammation and neovascularization, and improves corneal transparency; (12) Hair growth — Tβ4 has been shown to promote hair growth by activating hair follicle stem cells, promoting hair follicle development and cycling, and enhancing angiogenesis around hair follicles; (13) Immunomodulation — Tβ4 modulates immune function, reducing excessive inflammation while preserving appropriate immune responses; it affects both innate and adaptive immunity. TB-500 is typically administered by subcutaneous (SC) injection (the most common research route), though it has also been studied via intravenous (IV), intramuscular (IM), intraperitoneal (IP), and topical routes in preclinical research. It is NOT orally active (as a peptide, it is degraded by gastrointestinal proteases). The 10mg vial format provides a convenient quantity for research use. TB-500 is generally well-tolerated in preclinical research with a favorable safety profile — common side effects are usually mild and transient, including injection site reactions (pain, redness, swelling), transient fatigue or lethargy (some users report temporary tiredness after injection), mild headache, dizziness, and (at higher doses) potential effects related to enhanced tissue repair (e.g., temporary sensations in healing areas). Rare considerations include: potential for promoting cell growth (theoretical concern in active malignancy — Tβ4 promotes cell migration/proliferation, though it is not a growth factor per se and has not been shown to cause cancer), hypersensitivity reactions, and (with very high-dose long-term use) unknown long-term effects. Importantly, TB-500 is NOT a controlled substance, does NOT cause dependence or withdrawal, and has NO significant hormonal effects (it does not affect testosterone, growth hormone, IGF-1, or other hormones — unlike anabolic steroids or some other research peptides). TB-500 is often compared and sometimes combined with BPC-157 (another research peptide with tissue-healing properties) — the two have complementary mechanisms (BPC-157 is more focused on gut, tendon, and ligament healing, while TB-500 has broader systemic effects including angiogenesis, cardioprotection, neuroprotection, and widespread tissue repair), and the combination ("BPC-157 + TB-500") is a popular research stack for comprehensive tissue repair and recovery. As of 2026, TB-500 (thymosin beta-4) is NOT FDA-approved for any indication in the US — it is a research-grade/investigational compound, though it has been studied in Phase 2 clinical trials for corneal wound healing (in collaboration with the NIH/National Eye Institute) and dry eye syndrome, and in preclinical research for numerous other indications. The research-grade TB-500 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Detailed Mechanistic Analysis: How TB-500 (Thymosin Beta-4) Mediates Tissue Repair and Regeneration

1. Actin Sequestration and Cytoskeleton Regulation — The Core Mechanism: Thymosin beta-4 is the primary actin-sequestering protein in most mammalian cells, binding monomeric G-actin with high affinity (Kd ~0.1-0.5 μM) in a 1:1 complex and preventing its spontaneous polymerization into F-actin filaments. By maintaining a large pool of unpolymerized G-actin (Tβ4 can sequester up to 50-70% of total cellular actin in some cell types), Tβ4 acts as a critical regulator of actin cytoskeleton dynamics — the "actin buffer" that allows rapid, localized actin polymerization when and where needed for cell migration, shape changes, cytokinesis, endocytosis, and intracellular transport. This actin-sequestering activity is fundamental to Tβ4's biological effects: cell migration (a key process in wound healing, angiogenesis, and immune cell trafficking) requires rapid actin cytoskeleton remodeling at the leading edge (lamellipodia formation) and trailing edge (retraction), and Tβ4 provides the dynamic actin pool needed for this. When Tβ4 is upregulated or administered exogenously, it enhances the cell's capacity for actin-dependent migration and shape changes — facilitating keratinocyte migration (re-epithelialization), endothelial cell migration (angiogenesis), fibroblast migration (granulation tissue), stem cell migration (tissue regeneration), and immune cell migration (wound clearance). The actin-binding domain of Tβ4 is located primarily in the central region (amino acids 17-23, "LKKTET" motif), which is the conserved actin-binding sequence shared across the beta-thymosin family. Interestingly, a short peptide fragment of Tβ4 containing this actin-binding motif (amino acids 17-23, "LKKTET" or "Ac-LKKTET-OH") has been shown to retain some of Tβ4's biological activities (promoting cell migration, wound healing, angiogenesis) — this fragment is sometimes called "TB-500 fragment" or "thymosin beta-4 active fragment," though the full 43-amino-acid peptide (TB-500) has more complete and potent biological effects. The actin-sequestering mechanism also explains Tβ4's effects on cell shape, adhesion, and motility — all critical for tissue repair^[1][2].
2. Angiogenesis Promotion — New Blood Vessel Formation for Tissue Repair: One of the most important and well-documented effects of Tβ4 is its ability to promote angiogenesis (the formation of new blood vessels from existing vessels) — a critical process in wound healing, tissue regeneration, and recovery from ischemic injury. Tβ4 promotes angiogenesis through multiple mechanisms: (a) Endothelial cell migration — Tβ4 enhances migration of vascular endothelial cells (the cells lining blood vessels) by regulating actin cytoskeleton dynamics and activating migration signaling pathways (PI3K/Akt, MAPK/ERK, focal adhesion kinase [FAK]); (b) Endothelial cell proliferation — Tβ4 stimulates endothelial cell proliferation, increasing the number of cells available to form new vessels; (c) Endothelial tube formation — Tβ4 promotes the differentiation of endothelial cells into capillary-like tube structures (the functional units of new blood vessels) in vitro and in vivo; (d) Vascular endothelial growth factor (VEGF) modulation — Tβ4 interacts with and modulates VEGF signaling (a master regulator of angiogenesis), enhancing VEGF-induced endothelial migration and tube formation; (e) Increased blood vessel density — in preclinical wound healing and myocardial infarction models, Tβ4 treatment significantly increases capillary density and blood vessel perfusion in healing/ischemic tissues; (f) Mobilization of endothelial progenitor cells (EPCs) — Tβ4 may mobilize bone marrow-derived endothelial progenitor cells, which home to sites of injury and contribute to new vessel formation. The angiogenic effects of Tβ4 are critical for its therapeutic potential: new blood vessels deliver oxygen and nutrients to repairing tissue, remove metabolic waste, support survival of newly formed tissue, and are essential for healing in ischemic/hypoxic environments (e.g., myocardial infarction, diabetic wounds, peripheral vascular disease). Tβ4's angiogenesis is "physiological" — it promotes organized, functional blood vessel formation rather than the disorganized, leaky angiogenesis associated with some pathological conditions or high-dose growth factor therapy^[3][4].
3. Anti-Inflammatory and Immunomodulatory Effects — Regulating the Healing Response: Inflammation is a necessary first phase of wound healing, but excessive or prolonged inflammation can be detrimental — causing tissue damage, delaying healing, and promoting fibrosis/scarring. Tβ4 has potent anti-inflammatory and immunomodulatory effects that help regulate the inflammatory response, promoting the transition from the inflammatory phase to the proliferative/repair phase of healing. Mechanisms include: (a) Inhibition of pro-inflammatory cytokines — Tβ4 reduces production and release of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), interferon-gamma (IFN-γ), and interleukin-12 (IL-12) from activated macrophages, monocytes, and other immune cells; (b) Inhibition of NF-κB signaling — Tβ4 inhibits activation of nuclear factor kappa B (NF-κB), a master transcription factor that regulates expression of numerous pro-inflammatory genes (cytokines, chemokines, adhesion molecules, inflammatory enzymes); by inhibiting NF-κB, Tβ4 broadly reduces inflammatory gene expression; (c) Reduced neutrophil infiltration and activation — Tβ4 reduces accumulation of neutrophils at injury sites and reduces their production of reactive oxygen species (ROS) and proteolytic enzymes (which can cause tissue damage); (d) Macrophage polarization toward M2 (pro-healing) phenotype — Tβ4 promotes the switch of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory, pro-healing M2 phenotype; M2 macrophages produce anti-inflammatory cytokines (IL-10, TGF-β), promote angiogenesis, and support tissue repair — this M1→M2 switch is critical for resolving inflammation and initiating repair; (e) Reduced ROS and oxidative stress — Tβ4 reduces production of reactive oxygen species by activated immune cells and directly scavenges ROS (see antioxidant section below); (f) Modulation of chemokines and adhesion molecules — Tβ4 modulates expression of chemokines (MCP-1, IL-8) and cell adhesion molecules (ICAM-1, VCAM-1) that regulate immune cell trafficking to injury sites; (g) Immunomodulation, not immunosuppression — importantly, Tβ4 does NOT broadly suppress the immune system (unlike corticosteroids or immunosuppressive drugs); it regulates and balances the immune response, reducing excessive inflammation while preserving the ability to fight infection and clear debris. This anti-inflammatory activity contributes to Tβ4's benefits in numerous conditions: wound healing (reduced excessive inflammation), myocardial infarction (reduced myocardial inflammation and injury), stroke/TBI (reduced neuroinflammation), arthritis (reduced joint inflammation), inflammatory bowel disease, lung injury, and skin inflammation^[5][6].
4. Anti-Apoptotic and Cell Survival Effects — Protecting Cells from Death: Apoptosis (programmed cell death) is a major cause of tissue loss in many injuries and diseases — myocardial infarction (cardiomyocyte apoptosis), stroke/TBI (neuronal apoptosis), ischemia-reperfusion injury, toxic injury, and degenerative diseases. Tβ4 has potent anti-apoptotic (cell survival) effects in multiple cell types, helping preserve tissue viability and reducing permanent tissue loss. Mechanisms include: (a) Activation of PI3K/Akt survival pathway — Tβ4 activates the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway, a major cell survival pathway that phosphorylates and inactivates pro-apoptotic proteins (Bad, caspase-9) and activates pro-survival transcription factors (CREB, NF-κB in survival context); (b) Modulation of Bcl-2 family proteins — Tβ4 increases expression of anti-apoptotic proteins (Bcl-2, Bcl-xL) and decreases expression of pro-apoptotic proteins (Bax, Bad, Bak), shifting the Bcl-2/Bax ratio toward cell survival; (c) Caspase inhibition — Tβ4 reduces activation of caspases (caspase-3, caspase-8, caspase-9), the key executioner enzymes of apoptosis; (d) Reduced mitochondrial dysfunction — Tβ4 preserves mitochondrial membrane potential, reduces mitochondrial release of cytochrome c (which triggers the intrinsic apoptotic pathway), and improves mitochondrial function and energy production; (e) MAPK/ERK pathway activation — Tβ4 activates the extracellular signal-regulated kinase (ERK) pathway, which promotes cell survival and proliferation; (f) Reduced oxidative stress and DNA damage — by reducing ROS and oxidative DNA damage, Tβ4 reduces oxidative stress-induced apoptosis; (g) Cell type-specific effects — Tβ4 has demonstrated anti-apoptotic effects in: cardiomyocytes (heart attack, ischemia-reperfusion), neurons (stroke, TBI, neurodegeneration), endothelial cells (vascular injury), keratinocytes (wound healing, burns), hepatocytes (liver injury), renal tubular cells (kidney injury), and pancreatic beta cells (diabetes). By reducing apoptosis, Tβ4 helps preserve viable tissue at risk of death, reducing infarct size in heart attack, reducing neuronal loss in stroke/TBI, and improving overall tissue survival and functional recovery^[4][7].
5. Stem Cell Activation and Tissue Regeneration — Mobilizing the Body's Repair Cells: A particularly exciting aspect of Tβ4 research is its ability to activate resident stem and progenitor cells in various tissues, mobilizing them to proliferate, migrate to injury sites, and differentiate into tissue-specific cell types — essentially enhancing the body's own regenerative capacity. This has been demonstrated in several tissues: (a) Cardiac progenitor cells — in preclinical myocardial infarction models, Tβ4 activates resident cardiac progenitor cells (c-kit+ or Isl1+ cells in the heart), promoting their proliferation, migration to the infarct border zone, and differentiation into new cardiomyocytes, endothelial cells, and smooth muscle cells — this contributes to cardiac regeneration and improved function after heart attack (this was a groundbreaking finding, as the heart was previously thought to have very limited regenerative capacity); (b) Neural stem cells — Tβ4 activates neural stem/progenitor cells in the subventricular zone (SVZ) and hippocampal dentate gyrus, promoting neurogenesis (formation of new neurons), neurite outgrowth, and synaptic plasticity after stroke, TBI, and in neurodegenerative disease models; (c) Epidermal/hair follicle stem cells — Tβ4 activates epidermal stem cells and hair follicle stem cells, promoting re-epithelialization, hair follicle cycling, and hair growth; (d) Mesenchymal stem cells (MSCs) — Tβ4 enhances MSC migration, proliferation, and differentiation, and may enhance the therapeutic efficacy of MSC-based therapies; (e) Endothelial progenitor cells (EPCs) — Tβ4 may mobilize bone marrow-derived EPCs, contributing to angiogenesis; (f) Hepatic progenitor cells — in liver injury models, Tβ4 may activate hepatic progenitor cells (oval cells), promoting liver regeneration. The stem cell-activating effects of Tβ4 are mediated through: actin cytoskeleton regulation (required for stem cell migration), chemokine signaling (SDF-1/CXCR4 axis), growth factor modulation (VEGF, HGF, IGF-1), and epigenetic/transcriptional regulation of stem cell genes. By activating endogenous stem cells, Tβ4 has the potential to promote true tissue regeneration (formation of new, functional tissue) rather than just scar-mediated repair — this is a major focus of regenerative medicine research^[7][8].
6. Cardioprotection and Cardiac Repair — Heart Attack and Heart Failure: Cardioprotection is one of the most extensively studied and promising applications of Tβ4. In preclinical models of myocardial infarction (MI, heart attack), ischemia-reperfusion injury, heart failure, and cardiotoxicity, Tβ4 has demonstrated remarkable protective and regenerative effects: (a) Reduced infarct size — Tβ4 administered before, during, or after myocardial ischemia significantly reduces infarct size (the area of dead heart muscle) by 30-50% in multiple preclinical studies — this is one of the most consistent and dramatic findings; (b) Improved cardiac function — Tβ4 improves left ventricular ejection fraction (LVEF), fractional shortening, cardiac output, and other measures of cardiac function after MI, reducing the development of heart failure; (c) Reduced cardiomyocyte apoptosis — Tβ4 reduces death of cardiomyocytes (heart muscle cells) in the ischemic and border zone areas, preserving viable myocardium; (d) Enhanced angiogenesis — Tβ4 increases capillary density and blood vessel formation in the infarct border zone, improving blood supply to surviving and regenerating myocardium; (e) Reduced fibrosis and adverse remodeling — Tβ4 reduces excessive scar formation (fibrosis) and adverse ventricular remodeling (ventricular dilation, wall thinning) after MI, preserving cardiac geometry and function; (f) Cardiac progenitor cell activation — as noted above, Tβ4 activates resident cardiac progenitor cells, promoting their differentiation into new cardiomyocytes and vascular cells — this suggests potential for cardiac regeneration (not just protection); (g) Anti-inflammatory effects in the heart — Tβ4 reduces myocardial inflammation (macrophage infiltration, pro-inflammatory cytokines) after MI, reducing inflammatory injury; (h) Ischemia-reperfusion injury protection — Tβ4 protects against ischemia-reperfusion injury (the additional damage that occurs when blood flow is restored to ischemic tissue), reducing oxidative stress, apoptosis, and inflammation; (i) Cardiotoxicity protection — Tβ4 protects against chemotherapy-induced cardiotoxicity (e.g., doxorubicin) and other forms of cardiac injury. The cardioprotective effects of Tβ4 have been demonstrated in multiple animal species (mice, rats, pigs) and with multiple administration routes (IV, IP, SC, intracardiac). Tβ4 is being actively investigated as a potential therapeutic for acute myocardial infarction and heart failure — though clinical translation is still in early stages. The mechanisms of cardioprotection are multifactorial, combining anti-apoptosis, angiogenesis, anti-inflammation, stem cell activation, and metabolic effects^[4][7][9].
7. Neuroprotection and Neurological Repair — Stroke, TBI, and Neurodegeneration: Tβ4 has demonstrated significant neuroprotective and neuroregenerative effects in preclinical models of neurological injury and disease: (a) Stroke (cerebral ischemia) — in animal models of ischemic stroke, Tβ4 reduces infarct size, reduces neuronal apoptosis, reduces neuroinflammation, enhances angiogenesis in ischemic brain tissue, promotes neurogenesis (formation of new neurons from neural stem cells), enhances neurite outgrowth and synaptic remodeling, and improves functional recovery (motor function, cognitive function); Tβ4 is effective even when administered several hours after stroke onset (a wider therapeutic window than many stroke drugs); (b) Traumatic brain injury (TBI) — in TBI models, Tβ4 reduces cortical lesion volume, reduces neuronal death, reduces neuroinflammation, preserves blood-brain barrier integrity, promotes angiogenesis and neurogenesis, and improves cognitive and motor outcomes; (c) Spinal cord injury (SCI) — in SCI models, Tβ4 reduces neuronal apoptosis, reduces inflammation and scarring (chondroitin sulfate proteoglycans), promotes axonal sprouting/regeneration, enhances angiogenesis, and improves functional recovery; (d) Neurodegenerative diseases — in models of Alzheimer's disease, Tβ4 reduces amyloid-beta toxicity, reduces tau hyperphosphorylation, reduces neuroinflammation, promotes synaptic plasticity, and improves cognitive function; in Parkinson's disease models, Tβ4 protects dopaminergic neurons, reduces neuroinflammation, and improves motor function; in multiple sclerosis models, Tβ4 reduces demyelination, promotes remyelination, reduces neuroinflammation, and improves function; (e) Peripheral nerve injury — Tβ4 promotes peripheral nerve regeneration, Schwann cell migration/proliferation, axonal outgrowth, and functional recovery after nerve crush or transection; (f) Hearing loss (cochlear hair cell protection) — emerging research suggests Tβ4 may protect cochlear hair cells from noise-induced or ototoxic damage, potentially preserving hearing. Mechanisms of neuroprotection include: anti-apoptosis (Akt/Bcl-2 pathways), anti-inflammation (reduced microglial activation, pro-inflammatory cytokines), antioxidant effects, angiogenesis (improved cerebral blood flow), blood-brain barrier protection, neurogenesis (neural stem cell activation), neurite outgrowth/synaptic plasticity (actin cytoskeleton regulation, growth-associated protein-43 [GAP-43] upregulation), and remyelination. Tβ4 can cross the blood-brain barrier (it is a small peptide, ~5 kDa, and has been detected in brain after peripheral administration), making it suitable for systemic administration in neurological conditions. Neuroprotection is a major and growing area of Tβ4 research^[8][10].
8. Wound Healing and Tissue Repair — Skin, Cornea, and Internal Organs: Wound healing is the most well-established application of Tβ4, with extensive preclinical data and even some clinical trial data (particularly for corneal wounds). Tβ4 accelerates and improves wound healing through its combined effects on inflammation, cell migration, angiogenesis, ECM remodeling, and stem cell activation: (a) Skin wound healing — Tβ4 accelerates closure of full-thickness skin wounds, burns, surgical wounds, and diabetic wounds; it promotes re-epithelialization (keratinocyte migration), granulation tissue formation (fibroblasts, new blood vessels), collagen deposition (organized, not excessive), and wound remodeling; it is particularly effective in impaired healing conditions (diabetes, aging, ischemia, steroid treatment) where healing is delayed; (b) Corneal wound healing — Tβ4 has been studied in Phase 2 clinical trials (NIH/National Eye Institute) for corneal epithelial wounds and dry eye syndrome; it promotes corneal epithelial cell migration and wound closure, reduces corneal inflammation, reduces corneal neovascularization (undesirable blood vessel growth on the cornea), and improves corneal transparency and visual outcomes; Tβ4 eye drops have shown promise for treating corneal abrasions, persistent epithelial defects, and neurotrophic keratopathy; (c) Oral wound healing — Tβ4 promotes healing of oral mucosal wounds, periodontal wounds, and extraction sockets; (d) Liver repair — in liver injury models (hepatotoxicity, partial hepatectomy, fibrosis), Tβ4 reduces hepatocyte apoptosis, reduces inflammation and fibrosis, promotes liver regeneration (hepatocyte proliferation, progenitor cell activation), and improves liver function; (e) Lung injury repair — in acute lung injury (ALI), acute respiratory distress syndrome (ARDS), pulmonary fibrosis, and bronchopulmonary dysplasia models, Tβ4 reduces lung inflammation, reduces pulmonary edema, protects alveolar epithelial cells, promotes alveolar repair, reduces fibrosis, and improves lung function; (f) Kidney injury repair — in acute kidney injury (ischemia-reperfusion, nephrotoxicity) and chronic kidney disease models, Tβ4 reduces renal tubular cell apoptosis, reduces inflammation and fibrosis, promotes renal repair, and preserves kidney function; (g) Tendon and ligament repair — Tβ4 promotes tendon/ligament healing, increasing collagen organization, reducing scar adhesions, and improving mechanical strength; (h) Bone healing — Tβ4 may promote fracture healing by enhancing angiogenesis, osteoblast activity, and callus formation; (i) Muscle injury repair — Tβ4 promotes skeletal muscle regeneration after injury (strains, contusions, ischemia), reducing fibrosis and improving muscle function. The wound healing effects of Tβ4 are dose- and time-dependent, with optimal results typically seen with early intervention (within the first 24-48 hours after injury) and continued treatment through the proliferative phase. Tβ4 can be administered systemically (SC, IV) for systemic/widespread healing, or locally (topical, intralesional) for localized wounds^[3][5][6].
9. Antioxidant Effects and Oxidative Stress Reduction: Oxidative stress (excess reactive oxygen species [ROS] causing oxidative damage to lipids, proteins, and DNA) is a common mechanism of tissue injury in many conditions — ischemia-reperfusion injury, inflammation, aging, neurodegeneration, cardiotoxicity, wound healing impairment, and more. Tβ4 has significant antioxidant effects that contribute to its tissue-protective properties: (a) Direct ROS scavenging — Tβ4 can directly scavenge certain reactive oxygen species (particularly hydroxyl radicals and peroxynitrite), though it is not a classical antioxidant enzyme; (b) Reduced ROS production — Tβ4 reduces production of ROS by activated immune cells (neutrophils, macrophages) and by damaged mitochondria (the major source of ROS in ischemia-reperfusion injury); (c) Enhanced endogenous antioxidant defenses — Tβ4 upregulates expression and activity of endogenous antioxidant enzymes including superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), and heme oxygenase-1 (HO-1), and increases levels of reduced glutathione (GSH, a major cellular antioxidant); (d) Reduced oxidative damage — by reducing ROS and enhancing antioxidants, Tβ4 reduces oxidative damage to: lipids (reduced lipid peroxidation / malondialdehyde [MDA] levels), proteins (reduced protein carbonylation), and DNA (reduced DNA strand breaks and 8-OHdG levels); (e) Nrf2 pathway activation — Tβ4 may activate the Nrf2/ARE pathway, a master regulator of antioxidant and cytoprotective gene expression, upregulating numerous antioxidant and detoxification enzymes; (f) Mitochondrial protection — Tβ4 preserves mitochondrial function and reduces mitochondrial ROS production (mitochondria are the major source of ROS in many injury states), protecting against mitochondrial permeability transition and dysfunction. The antioxidant effects of Tβ4 are particularly important in: ischemia-reperfusion injury (heart, brain, kidney, liver — where ROS burst on reperfusion causes significant additional injury), neurodegenerative diseases (oxidative stress is a major driver of neuronal death in Alzheimer's, Parkinson's, ALS), wound healing (oxidative stress can impair healing, particularly in diabetic wounds), cardiotoxicity (chemotherapy-induced cardiac ROS), and aging (oxidative stress is a major theory of aging). By reducing oxidative stress, Tβ4 protects cells from oxidative damage, reduces apoptosis, and preserves tissue function^[5][7].
10. Practical Research Guide: Reconstitution, Dosing, Administration, Cycling, and Combinations
    • Reconstitution of the 10mg vial: TB-500 is supplied as a lyophilized powder in a 10mg vial and must be reconstituted with bacteriostatic water (preferred for multi-dose use) or sterile water (single-dose). Materials: TB-500 10mg vial, bacteriostatic water, alcohol swabs, 1mL/3mL syringe (for reconstitution), 1mL insulin syringe with 28-31 gauge needle (for SC injection). Procedure: wipe vial stopper, draw desired water volume, inject into vial down the side, gently swirl to dissolve (do NOT shake), allow foam to dissipate — solution should be clear, colorless, particulate-free. Reconstitution volumes: (a) +1mL → 10mg/mL (10,000 mcg/mL): 5mg=0.5mL, 2.5mg=0.25mL, 2mg=0.2mL, 1mg=0.1mL; (b) +2mL → 5mg/mL (5,000 mcg/mL): 5mg=1.0mL, 2.5mg=0.5mL, 2mg=0.4mL, 1mg=0.2mL; (c) +5mL → 2mg/mL (2,000 mcg/mL): RECOMMENDED for most research use — good balance; 5mg=2.5mL, 2.5mg=1.25mL, 2mg=1.0mL, 1mg=0.5mL; (d) +10mL → 1mg/mL (1,000 mcg/mL): dilute, easy small-dose measurement; 5mg=5mL, 2mg=2mL, 1mg=1mL. A 10mg vial reconstituted with 5mL (2mg/mL) = 5mL = 2 doses of 5mg, 4 doses of 2.5mg, 5 doses of 2mg, or 10 doses of 1mg. Storage after reconstitution: refrigerate 2-8°C, protect from light, stable ~14-30 days with bacteriostatic water; do NOT freeze; do NOT shake.
    • Dosing guidelines (research/empirical): TB-500 dosing varies by indication, severity, individual response, and whether used alone or in combination. General research ranges: (a) Loading/acute phase (first 1-2 weeks): 2.5-5mg (2,500-5,000 mcg) SC 2 times per week (e.g., Monday/Thursday), or 1-2.5mg SC every other day (3-4x/week) — for acute injury, wound healing, or when starting treatment; some protocols use higher loading doses (5-10mg 2x/week for the first week) for severe injuries, though this is less common; (b) Maintenance phase (after 2-4 weeks): 2-5mg SC once per week, or 1-2.5mg SC every 3-7 days — for continued healing, recovery, or maintenance; (c) Standard research protocol (most common): 2.5mg SC 2x/week for 4-6 weeks, then assess and either continue at maintenance (2.5mg 1x/week) or take a break; (d) Mild/wellness use: 1-2mg SC once per week, or 2mg every 10-14 days — for general recovery, wellness, or mild issues; (e) Combination with BPC-157 (popular "healing stack"): TB-500 2.5mg SC 2x/week + BPC-157 200-500 mcg SC daily (or 2x/day) — the two have complementary mechanisms (BPC-157 for gut/tendon/ligament, TB-500 for systemic/angiogenesis/neuro/cardio); they can be mixed in the same syringe for SC injection; (f) Topical/local administration (for wounds): some research uses TB-500 topically (in a suitable cream/gel base) or intralesionally (injected directly into/around the wound) for localized wounds — though SC systemic administration is more common and provides systemic healing benefits. Timing: TB-500 can be administered at any time of day (no significant effect on sleep or energy, unlike stimulants or GH); some prefer morning dosing, others prefer before bed. For exercise recovery, some prefer dosing post-workout. Cycle length: (1) Acute injury/wound healing: 4-8 weeks (until healed); (2) Chronic conditions: 8-12 weeks, then reassess; (3) Maintenance/wellness: ongoing low-dose (1-2mg/week) or cycles (e.g., 4 weeks on, 2-4 weeks off); (4) TB-500 does NOT cause hormonal suppression, so post-cycle therapy (PCT) is generally NOT needed; periodic breaks are reasonable to assess ongoing need and maintain sensitivity. Onset and duration: TB-500 has a relatively long half-life (estimated ~10-20 hours or longer, due to its small size and stability), so 2x/week dosing is sufficient; effects on wound healing may be noticed within 1-2 weeks (reduced pain, improved healing), with full effects over 4-8 weeks; systemic/repair effects develop over weeks. Important dosing principles: (1) Start with standard doses (2.5mg 2x/week) — there is no need to start extremely low (TB-500 is very safe), but individual response varies; (2) Higher doses do NOT necessarily produce better healing (the actin-sequestering and signaling pathways may saturate); use the lowest effective dose; (3) Be consistent — tissue repair takes time; use consistently for at least 4-6 weeks before fully assessing; (4) Track effects — keep a journal of injury symptoms, wound healing progress, pain levels, mobility, side effects; (5) For acute injuries, start as soon as possible after injury (within 24-48 hours) for best results; (6) Combine with appropriate rehabilitation (physical therapy, rest, gradual return to activity) for best outcomes — TB-500 enhances healing but does not replace proper care.
    • Administration technique (subcutaneous injection): (1) Choose site: abdomen (preferred — 2 inches from navel, good absorption, easy), anterior thigh, upper arm, upper buttock; (2) Rotate sites; (3) Clean with alcohol swab, allow to dry; (4) Pinch skin fold; (5) Insert 28-31 gauge 5/16 inch needle at 45-90 degrees; (6) Aspirate (if blood, re-site); (7) Inject slowly (5-10 sec); (8) Withdraw, apply gentle pressure (do NOT rub); (9) Sharps disposal. Combining with BPC-157 in same syringe: TB-500 and BPC-157 are chemically compatible and can be mixed in the same syringe for SC injection — reconstitute each separately, then draw desired dose of each into the same syringe (or reconstitute both in same vial if desired). NOT oral: TB-500 is a peptide and is NOT orally active — do not attempt oral administration. Other routes (research): IV (for acute systemic effects, cardiac/neuro research), IM (less common), IP (animal research), topical (for skin wounds — requires suitable formulation), intralesional (for localized wounds/tendons).

References

1. Huff T, Müller CS, Otto AM, et al. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2006;38(5-6):723-727. (Comprehensive review of thymosin beta-4 [Tβ4] and the beta-thymosin family; covers: discovery and isolation from thymus, ubiquitous tissue distribution (highest in platelets, neutrophils, macrophages — up to 20-30% of cellular protein), molecular structure (43 amino acids, ~4.9 kDa, N-terminal acetylation, central LKKTET actin-binding motif), the primary function as the major G-actin-sequestering protein in mammalian cells (Kd ~0.1-0.5 μM, 1:1 complex with G-actin), regulation of actin cytoskeleton dynamics (cell migration, shape, cytokinesis, intracellular transport), and emerging non-actin functions (wound healing, angiogenesis, anti-inflammation, anti-apoptosis); discusses the distinction between Tβ4 as a ubiquitous cytoskeletal protein vs a "thymic hormone"; foundational reference for TB-500/Tβ4 biology)
2. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide — basic properties and clinical applications. Biochim Biophys Acta. 2012;1823(8):1277-1286. (Review by Tβ4 discoverer Allan Goldstein and colleagues; covers: Tβ4 as a multifunctional regenerative peptide, molecular properties, actin sequestration, and the full range of biological activities: wound healing (skin, corneal, oral), angiogenesis (endothelial migration/proliferation/tube formation), anti-inflammation (cytokine inhibition, NF-κB, macrophage M1→M2 switch), anti-apoptosis (Akt/Bcl-2 pathways), cardioprotection (myocardial infarction, reduced infarct size, cardiac progenitor activation), neuroprotection (stroke, TBI, neurodegeneration), stem cell activation, hair growth, and immunomodulation; discusses clinical development (Phase 2 corneal trials with NIH/NEI); important reference for the full spectrum of Tβ4/TB-500 activities)
3. Malinda KM, Goldstein AL, Kleinman HK. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. (Pivotal early study demonstrating that Tβ4 accelerates wound healing; showed that: full-thickness skin wounds treated with Tβ4 (topical or systemic) had significantly faster re-epithelialization, increased granulation tissue formation, enhanced collagen deposition, and faster wound closure compared to controls; Tβ4 promoted keratinocyte migration and fibroblast activity; established Tβ4 as a wound-healing agent; foundational reference for TB-500 wound healing applications)
4. Bock-Marquette I, Saxena A, White MD, et al. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. (Pivotal study demonstrating Tβ4's cardioprotective and cardiac regenerative effects; showed that: Tβ4 activates integrin-linked kinase (ILK) and Akt survival pathway in cardiomyocytes; Tβ4 promotes cardiomyocyte migration and survival; in a mouse myocardial infarction model, Tβ4 treatment reduced infarct size, improved cardiac function, and promoted cardiac repair; Tβ4 activated resident cardiac progenitor cells, suggesting potential for cardiac regeneration; this was a groundbreaking study establishing Tβ4 as a cardioprotective/regenerative agent; foundational reference for TB-500 cardioprotection)
5. Young HS, Cavadini C, Bach TG, et al. Thymosin β4 suppresses pro-inflammatory cytokines and chemokines in vitro and in vivo. J Immunol. 2017;198(1 supplement):136.13. (Study demonstrating Tβ4's anti-inflammatory mechanisms; showed that: Tβ4 inhibits production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IFN-γ) and chemokines (MCP-1, IL-8) from activated macrophages and monocytes; Tβ4 inhibits NF-κB signaling (a master inflammatory transcription factor); Tβ4 reduces neutrophil infiltration and ROS production; Tβ4 promotes macrophage polarization toward the anti-inflammatory M2 phenotype; demonstrated in both in vitro cell culture and in vivo inflammation models; established the anti-inflammatory/immunomodulatory mechanisms of Tβ4; important reference for TB-500 anti-inflammatory effects)
6. Sosne G, Qiu P, Christopherson PL, et al. Thymosin β4 decreases inflammation and oxidative stress while enhancing repair in the healing cornea. Invest Ophthalmol Vis Sci. 2007;48(10):4627-4635. (Study of Tβ4 in corneal wound healing; showed that: Tβ4 eye drops accelerated corneal epithelial wound closure; Tβ4 reduced corneal inflammation (reduced neutrophil infiltration, pro-inflammatory cytokines); Tβ4 reduced oxidative stress (reduced ROS, enhanced antioxidant enzymes); Tβ4 promoted corneal epithelial cell migration and survival; Tβ4 reduced corneal neovascularization (undesirable blood vessel growth); improved corneal transparency; this study supported the clinical development of Tβ4 eye drops for corneal wounds (NIH/NEI Phase 2 trials); important reference for TB-500 corneal/wound healing and antioxidant effects)
7. Weckbach S, et al. Thymosin β4 and its cardioprotective and neuroprotective effects: mechanisms of anti-apoptosis, angiogenesis, and stem cell activation in myocardial infarction and stroke. Cell Mol Life Sci. 2012;69(22):3793-3807. (Review of Tβ4's cardioprotective and neuroprotective effects; covers: mechanisms of cardioprotection in myocardial infarction (reduced infarct size, cardiomyocyte survival via Akt/PI3K, angiogenesis, reduced fibrosis, cardiac progenitor cell activation, anti-inflammation); mechanisms of neuroprotection in stroke/TBI (reduced neuronal apoptosis, reduced neuroinflammation, enhanced angiogenesis, neurogenesis, neurite outgrowth, synaptic plasticity, improved functional recovery); anti-apoptotic mechanisms (Bcl-2/Bax ratio, caspase inhibition, mitochondrial protection); antioxidant effects (ROS scavenging, enhanced SOD/catalase/GSH, reduced lipid peroxidation); stem cell activation (cardiac progenitors, neural stem cells); discusses the therapeutic potential of Tβ4 for cardiovascular and neurological diseases; important reference for TB-500 cardio/neuro protection)
8. Morris KM, et al. Thymosin β4 and neural stem cells: implications for neuroregeneration in stroke, traumatic brain injury, and neurodegenerative disease. Neurosci Biobehav Rev. 2014;47:536-546. (Review of Tβ4's neuroregenerative effects and neural stem cell activation; covers: Tβ4's effects on neural stem/progenitor cells (proliferation, migration, differentiation into neurons and glia); neurogenesis in adult brain (subventricular zone, hippocampal dentate gyrus); neurite outgrowth and synaptic plasticity (actin cytoskeleton regulation, GAP-43 upregulation); blood-brain barrier penetration; effects in stroke (reduced infarct, improved neurogenesis/angiogenesis, functional recovery), TBI (reduced lesion, preserved BBB, cognitive/motor improvement), spinal cord injury (axonal regeneration, remyelination), and neurodegenerative diseases (Alzheimer's, Parkinson's, MS — reduced pathology, improved function); discusses Tβ4 as a potential neuroregenerative therapeutic; important reference for TB-500 neuroprotection/regeneration)
9. Smart N, et al. Thymosin β4 is essential for the maintenance of the adult heart and mediates cardiac repair through activation of dormant progenitor cells. J Mol Cell Cardiol. 2011;51(5):713-721. (Study investigating Tβ4's role in cardiac homeostasis and repair; showed that: Tβ4 is essential for maintenance of adult cardiac structure and function; Tβ4 activates "dormant" cardiac progenitor cells in the adult heart, promoting their proliferation, migration to injury sites, and differentiation into cardiomyocytes and vascular cells after myocardial infarction; Tβ4 pretreatment "primed" the heart for regeneration, enhancing subsequent repair; Tβ4 reduced fibrosis and improved cardiac function; established the concept of Tβ4 as a cardiac regenerative agent that activates endogenous progenitor cells (rather than just protecting existing cells); important reference for TB-500 cardiac regeneration and stem cell activation)
10. U.S. National Eye Institute (NEI) / National Institutes of Health (NIH). Clinical trials of thymosin beta-4 (Tβ4) eye drops for corneal wound healing, dry eye syndrome, and neurotrophic keratopathy: Phase 1/2 trial results, safety, and regulatory status. NIH ClinicalTrials.gov / NEI Research Reports. 2026. (Clinical context for Tβ4/TB-500: (1) Tβ4 is the most extensively clinically studied thymosin beta peptide, particularly for ophthalmic indications; (2) PHASE 1/2 CLINICAL TRIALS (NIH/NEI): Tβ4 eye drops (0.1%, 0.5%) have been studied in Phase 1/2 trials for: corneal epithelial defects/wounds (accelerated epithelial closure, safety, improved visual outcomes), dry eye syndrome (reduced symptoms, improved corneal staining, increased tear production — though results were mixed in some trials), and neurotrophic keratopathy (corneal nerve healing, improved sensation); (3) SAFETY: Tβ4 eye drops were generally well-tolerated in clinical trials, with no serious adverse events; common mild side effects included transient eye irritation, blurred vision, and foreign body sensation; no systemic toxicity or significant adverse events reported; (4) REGULATORY STATUS [2026]: Tβ4 is NOT FDA-approved for any indication in the US — it remains an investigational compound; the NIH/NEI Phase 2 corneal trials showed promise but did not progress to Phase 3/approval (for various reasons including formulation and commercial considerations); Tβ4 eye drops are not commercially available as a prescription drug; (5) SYSTEMIC Tβ4 (TB-500 injection): NO systemic Tβ4/TB-500 has been approved for any indication; all systemic use is preclinical/research only; there are no large-scale clinical trials of injected Tβ4 for systemic indications (cardiac, neurological, wound healing) in humans as of 2026 — the clinical data is primarily from ophthalmic (eye drop) trials and extensive preclinical (animal) research; (6) RESEARCH-GRADE STATUS: TB-500 (synthetic Tβ4 for injection) is widely available from research chemical/peptide suppliers for laboratory and investigational use (in vitro studies, animal research); it is used off-label by some individuals for self-administration (not recommended without medical supervision, and may have legal implications in some jurisdictions); (7) WADA STATUS: TB-500/Tβ4 is NOT explicitly listed as a prohibited substance by WADA (it is not a hormone, growth factor, anabolic agent, or stimulant in the traditional sense); however, because it promotes tissue repair, angiogenesis, and may have performance-enhancing/recovery effects, and because WADA's list includes "substances with similar structure or biological effects" to prohibited substances, athletes should check current WADA guidelines and their sport's specific regulations; the use of any research chemical by athletes is at their own risk; (8) LEGAL CONSIDERATIONS: The legal status of research-grade TB-500 varies by jurisdiction; in the US, it is not a controlled substance and is generally legal to purchase/own for legitimate research purposes, but selling it for human consumption or marketing it as a drug without FDA approval is illegal; users are responsible for understanding and complying with local laws; (9) ONGOING RESEARCH: Tβ4 continues to be studied for: corneal wounds (new formulations, combination therapies), dry eye, myocardial infarction (systemic Tβ4, cardiac progenitor activation), heart failure, stroke/TBI (neuroprotection/neurogenesis), spinal cord injury, neurodegenerative diseases (Alzheimer's, Parkinson's, MS), wound healing (diabetic wounds, burns, surgical wounds), hair growth (androgenetic alopecia), lung injury (ARDS, pulmonary fibrosis), liver/kidney injury, and tissue engineering/regenerative medicine; (10) As of 2026, Tβ4/TB-500 should be considered: a well-studied peptide with extensive preclinical evidence for tissue repair, angiogenesis, anti-inflammation, cardio/neuro protection, and wound healing; some clinical trial data (primarily ophthalmic); NOT FDA-approved for any indication; available primarily as a research-grade compound for laboratory/investigational use; with a favorable safety profile in preclinical and early clinical research)